Journal of Clinical Epidemiology
Volume 62, Issue 12 , Pages 1268-1278 , December 2009

Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations

  • Donna H. Odierna

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Clinical Pharmacy, University of California, San Francisco, 3333 California Street, Suite 410, San Francisco, CA 94118, USA. Tel.: 415-502-8227; fax: 415-502-0792.
    • ,
  • Lisa A. Bero

,Accepted 5 January 2009.

References 

  1. World Health Organization . Equitable access to essential medicines: a framework for collective action. In: W.H.O.  editors. WHO policy perspectives on medicines. Geneva, Switzerland: World Health Organization; 2004;
  2. World Health Organization . How to develop and implement a national drug policy. In: W.H.O.  editors. WHO policy perspectives on medicine. 2nd edition. Geneva, Switzerland: W.H.O.; 2001;
  3. McElwee NE, Ho SY, McGuigan KA, Horn ML. Evidence-based coverage decisions? Primum non nocere. Health Aff. 2006;25(4):279–282
  4. Whitehead M. The concepts and principles of equity and health. Health Promot Int. 1991;6(3):217–228
  5. Tugwell P, de Savigny D, Hawker G, Robinson V. Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ. 2006;332(7537):358–361
  6. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661–687
  7. Centers for Medicaid and Medicare Services Overview. U.S. Department of Health and Human Services. Available at: http://www.cms.hhs.gov/pf/printpage.asp?ref=http://www.cms.hhs.gov/MedicaidGenInfo/01_Overview.asp. Accessed November 14, 2008.
  8. Oregon Health and Science University . Drug effectiveness review project (DERP). 2008;Portland, OR. Available at: http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/index.cfm. Accessed June 26, 2008
  9. Elam L, Murawski MM, Childs S, Vanable JW. Patient safety forum: do state Medicaid preferred drug lists affect patient safety?. Psychiatr Serv. 2005;56(8):1012–1016
  10. Crowley J, Ashner D. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update. In: Kaiser commission on Medicaid and the uninsured. Washington, DC: Kaiser Family Foundation; 2005;
  11. Canadian Agency for Drugs and Technologies in Health . Common drug review. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2008;
  12. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0. Updated February 2008. In: The Cochrane Collaboration  editors. 2008;Available at www.cochrane-handbook.orgAccessed July 30, 2008
  13. Neumann PJ. Emerging lessons from the drug effectiveness review project. Health Aff. 2006;25(4):W262–W271
  14. Heaton AH. The DERP: is it an effective methodology?. Health Aff. 2006;25(4):W276–W278
  15. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med. 1997;127(1):37–42
  16. Sweet M, Moynihan R. Improving population health: the uses of systematic reviews. New York and Atlanta: Milbank Memorial Fund and Centers for Disease Control and Prevention; 2007;
  17. Findlay SD. Bringing the DERP to consumers: ‘consumer reports best buy drugs’. Health Aff. 2006;25(4):W283–W286
  18. Moynihan R. In: Millbank Memorial Fund  editors. Evaluating health services: a reporter covers the science of research synthesis. 2004;New York
  19. Fox DM. Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff. 2005;24(1):114–122
  20. Jewell C, Bero L. Developing good taste in evidence: facilitators and hindrances to evidence-informed health policy making in state government. Milbank Q. 2008;86(2):177–208
  21. U.S. Department of Health and Human Services . State strategies to contain Medicaid drug costs. In: Office of Inspector General  editors. 2003;Available at http://www.oig.hhs.gov/oei/reports/oei-05-02-00680.pdfAccessed October 1, 2008
  22. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–1170
  23. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007;335(7631):1202–1205
  24. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333(7572):782
  25. Gibson M. When good information truly matters: public sector decision makers acquiring and using research to inform their decisions. J Law Policy. 2006;XIV(2):551–568
  26. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff. 2004;23:135–146
  27. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med. 2008;168(2):133–135
  28. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71–72
  29. Centers for Medicaid and Medicare Services . Fiscal year 2004 national MSIS tables, in Medicaid statistical information system state summary FY2004. Available at http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/msistables2004.pdf2007;Accessed July 30, 2008
  30. Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community. 2004;12(5):382–388
  31. Heiat A, Gross CP, Krumholz H. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–1688
  32. Lee P, Alexander K, Bradley G, Pasquali S, Peterson E. Representation of elderly persons and women in trials of acute coronary syndromes. JAMA. 2001;296(6):708–713
  33. Rochon P, Mashari A, Cohen A, Anjali M, Laxer D, Streiner DL. The Inclusion of minority groups in clinical trials: problems of under representation and under reporting of data. Account Res. 2004;11(3–4):215–223
  34. Roberts D. Is race-based medicine good for us? African American approaches to race, biomedicine, and equality. J Law Med Ethics. 2008;36(3):471–477
  35. Swanson GM, Bailar JC. Selection and description of cancer clinical trials participants–science or happenstance?. Cancer. 2002;95(5):950–959
  36. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA. 2007;297(11):1233–1240
  37. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nature. 2008;14:510–517
  38. Exner D, Dries D, Domanski M, Cohen J. Lesser response to angiotensis-converting enzyme inhibitor therapy in black compared to white patients with left ventricular dysfunction. NEJM. 2001;344(18):1351–1357
  39. Cotton P. Examples abound of gaps in medical knowledge because of groups excluded from scientific study. JAMA. 1990;263(8):1051–1055
  40. Braun L, Fausto-Sterling A, Fullwiley D, Hammonds EM, Nelson A, Quivers W, et al. Racial categories in medical practice: how useful are they?. PLoS Med September 1. 2007;4(9):e271;doi:10.1371/journal.pmed.0040271
  41. Epstein S. Inclusion: the politics of difference in medical research. Chicago, IL: University of Chicago Press; 2007;
  42. Krieger N, Fee E. Man-made medicine and women's health: the biopolitics of sex/gender and race/ethnicity. In:  Krieger N editors. Embodying inequality: epidemiologic perspectives. Amityville, NY: Baywood; 2004;p. 239–256
  43. Kawachi I, Daniels N, Robinson DE. Health disparities by race and class: why both matter. Health Aff. 2005;24(2):343–352
  44. Ellison GTH, et al. Racial categories in medicine: a failure of evidence-based practice?. PLoS Medicine. September 01. 2007;4(9):e287;doi:210.1371/journal.pmed.0040287
  45. Caulfield T, Harry S. Popular representation of race: the news coverage of Bidil. J Law Med Ethics. 2008;36(3):485–490
  46. Obasogie OK. Beyond best practices: strict scrutiny as a regulatory model for race-specific medicines. J Law Med Ethics. 2008;36(3):491–497
  47. Winker MA. Measuring race and ethnicity: why and how?. JAMA. 2004;292(13):1612–1614
  48. Zuberi T. Thicker than blood: how racial statistics lie. Minneapolis, MN: Regents of University of Minnesota; 2001;
  49. van den Oord E, Rowe DC. A step in another direction: looking for maternal genetic and environmental effects on racial differences in birth weight. Demography. 2001;38(4):573–576
  50. Sankar P, Kahn J. BiDil: race medicine or race marketing?. Health Aff 10.1377/ October 11. 2005;hlthaff.w5.455-463
  51. Fine MJ, Ibrahim SA, Thomas SB. The role of race and genetics in health disparities research. Am J Public Health. 2005;076588
  52. Navarro V. Race or class versus race and class: mortality differentials in the United States. Lancet. 1990;336(8725):1238–1240
  53. Kaufman J. Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example. Soc Sci Med. 2008;66:1659–1669
  54. van den Oord E, Rowe DC. Racial differences in birth health risk: a quantitative genetic approach. Demography. 2000;37(3):285–298
  55. Williams DR, Jackson PB. Social sources of racial disparities in health. Health Aff. 2005;24(2):325–334
  56. Doyle JM. What race and ethnicity measure in pharmacologic research. J Clin Pharmacol. 2006;46(4):401–404
  57. Gwatkin DR. Health inequalities and the health of the poor: what do we know? What can we do?. Bull World Health Organ. 2000;78:3–17
  58. Syme SL, Berkman L. Social class, susceptibility, and sickness. Am J Epidemiol. 1976;104:1–8
  59. Marmot M. Social determinants of health inequalities. Lancet. 2005;365(9464):1099–1104
  60. In:  Syme S,  Reeder L editor. Social stress and cardiovascular disease. Vol. 45:New York: Milbank Memorial Fund Quarterly; 1967;
  61. Kawachi I, Subramanian SV. Neighbourhood influences on health. J Epidemiol Community Health. 2007;61(1):3–4
  62. Krieger N. Discrimination and health. In:  Berkman L,  Kawachi I editor. Social epidemiology. Oxford: Oxford University Press; 2000;p. 36–75
  63. Berkman L, Glass T. Social integration, social networks, social support, and health. In:  Berkman L,  Kawachi I editor. Social epidemiology. New York: Oxford University Press; 2000;p. 137–173
  64. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338(3):171–179
  65. Todd KH, Deaton C, D'Adamo A, Goe L. Ethnicity and analgesic practice. Ann Emerg Med. 2000;35:11–16
  66. Subramanian SV, Chen JT, Rehkopf DH, Waterman PD, Krieger N. Racial disparities in context: a multilevel analysis of neighborhood variations in poverty and excess mortality among black populations in Massachusetts. Am J Public Health. 2005;95:260–265
  67. Link BG, Phelan J. Social conditions as fundamental cause of disease. J Health Soc Behav. 1995;(Extra Issue):80–94
  68. Paul K, Boutain D, Manhart L, Hitti J. Racial disparity in bacterial vaginosis: the role of socioeconomic status, psychological stress, and neighborhood characteristics, and possible implications for preterm birth. Soc Sci Med. 2008;67:824–833
  69. Wang Y, Krishnsn HR, Ghezzi A, Yin JCP, Atkinson NS. Drug-induced epigenetic changes produced drug tolerance. PLoS Biol. 2007;5(10):e265
  70. Peedicayil J. The role of epigenetics in mental disorders. Indian J Med Res. 2007;126(August):105–111
  71. Francis DD, Szegda K, Campbell G, Martin WD, Insel TT. Epigenetic sources of behavioral differences in mice. Nat Neurosci. 2003;6(5):445–446
  72. Oregon Health and Science University . Documents: drug effectiveness review project final products. Drug Effectiveness Review Project. Oregon Health and Science University; 2008;Available at http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/final-products.cfmAccessed April 27, 2008
  73. Oregon Health and Science University . DERP methods. Drug Effectiveness Review Project. Oregon Health & Science University; 2008;Available at http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfmPortland, OR Accessed April 29, 2008
  74. The Kaiser Family Foundation, State Health Facts, statehealthfacts.org. Data Source: Centers for Medicare and Medicaid Services and U.S. Census Bureau Current Populations Surveys . The Kaiser Family Foundation. Available at http://www.statehealthfacts.org/2008;Accessed April 27, 2008
  75. The Kaiser Family Foundation, State Health Facts, Methodology, statehealthfacts.org, Sourcing, and Contact Information. 2008. Accessed August 1, 2008.
  76. Centers for Medicaid and Medicare Services . Medicaid at a glance 2005: a Medicaid information source. Washington, DC: US Department of Health and Human Services; 2005;Available at http://www.cms.hhs.gov/MedicaidGenInfo/Downloads/MedicaidAtAGlance2005.pdfAccessed July 30, 2008
  77. Centers for Medicaid and Medicare Services . Medicaid data sources—general information. U.S. Department of Health and Human Services; 2008;Available at http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/02_MSISData.aspAccessed July 30, 2008
  78. U.S. Census Bureau . State & county quickfacts. In: A.f.h.q.c.g.q.s.h. U.S. Census Bureau  editors. QuickFacts. 2007;
  79. U.S. Census Bureau . Profile of general demographic characteristics: 2006. American FactFinder. 2007;Available at http://factfinder.census.gov/home/saff/main.html%3F_lang=enAccessed April 24, 2008
  80. Mann J. Medicine and public health, ethics, and human rights (Hastings Center Report, 1997). In:  Beauchamp DE,  Steinbock B editor. New ethics for the public's health. 1999;p. 83–93
  81. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart. 2003;89:327–328
  82. Wendler D, Kington R, Madans J, Wye GV, Christ-Schmidt H, Pratt LA, et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med. 2006;3(2):e19
  83. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare coverage decisions. Arch Intern Med. 2008;168(2):136–140
  84. Tugwell P, Robinson V, Kristjansson E. The role of clinical epidemiology in health equity: let's take action!. J Clin Epidemiol. 2005;58(8):751–752
  85. MacLehose R, Reeves B, Harbvey I, Sheldon T, Russell I, Black A. A systematic review of comparisons of effect sizes derived from randomized and non-randomized studies. Health Technol Assess. 2000;4(34):1–154
  86. Mechanic D. Policy challenges in addressing racial disparities and improving population health. Health Aff. 2005;24(2):335–338
  87. CSDH . Closing the gap in a generation: health equity through action on the social determinants of health. Geneva, Switzerland: World Health Organization; 2008;
  88. Pollock A. Pharmaceutical meaning-making beyond marketing: racialized subjects of generic Thiazide. J Law Med Ethics. 2008;36(3):530–536
  89. Rothwell PM. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176–186
  90. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116(1):78–84
  91. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL. Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and health disparities. Am J Public Health. 2008;98(9):1608–1615
  92. Kavaganagh J, Oliver S, Lorenc T. Reflections on developing and using PROGRESS-Plus. In:  Tugwell P,  Welch V,  Morris E editor. Equity update. Ottawa, ON: The Cochrane Collaboration; 2008;
  93. Evans T, Brown H. Road traffic crashes: operationalizing equity in the context of health sector reform. Inj Control Saf Promot. 2002;10(1–2):11–12
  94. Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Am J Manag Care. 2001;8(1):69–76
  95. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98(7):1300–1305

PII: S0895-4356(09)00030-4

doi: 10.1016/j.jclinepi.2009.01.009

Journal of Clinical Epidemiology
Volume 62, Issue 12 , Pages 1268-1278 , December 2009

Article Tools